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Abstract:  
Background: Risankizumab, an anti-interleukin-23 antibody, was superior to placebo in 
achieving clinical and endoscopic remission at week 12 in a randomised, phase 2 induction 
study in patients with moderately to severely active Crohn’s disease. The efficacy and safety 
of extended intravenous induction and/or subcutaneous maintenance therapy with 
risankizumab was assessed. 
Methods: Following 12-week, double-blind, randomised, induction treatment comparing 200 
mg or 600 mg intravenous risankizumab to placebo every 4 weeks, patients without deep 
remission, defined as clinical (Crohn’s Disease Activity Index <150) and endoscopic 
remission (Crohn’s Disease Endoscopic Index of Severity [CDEIS] ≤4 [≤2 for patients with 
isolated ileitis]), received open-label 600 mg intravenous risankizumab (every 4 weeks) and 
patients in deep remission underwent washout until week 26 (Period 2). At week 26, patients 
in clinical remission received maintenance treatment (Period 3) with 180 mg subcutaneous 
risankizumab (every 8 weeks). Efficacy endpoints included clinical and endoscopic response 
and remission at weeks 26 (Period 2) and 52 (Period 3) respectively; safety was assessed 
through both periods. Study registration: ClinicalTrials.gov, NCT02031276. 
Findings: In Period 2, 101 patients were treated with 600 mg risankizumab resulting in an 
increase in clinical remission rates at week 26 versus week 12 for all original designated 
treatment groups: 55% versus 18%, 59% versus 21%, and 47% versus 26% for placebo, 200, 
and 600 mg risankizumab, respectively. Of the 62 patients receiving maintenance treatment, 
54 completed treatment. At week 52, clinical remission was maintained by 71% of patients; 
endoscopic remission and response (>50% CDEIS reduction from baseline) was achieved by 
35% and 55% of patients, respectively, and 29% of patients achieved deep remission. 
Risankizumab was well tolerated with no new safety signals. 
Interpretation: Extended induction treatment with open-label intravenous risankizumab was 
effective in increasing clinical response and remission rates at week 26. Open-label 
subcutaneous risankizumab maintained remission till week 52 in most patients who were in 
clinical remission at week 26. Selective blockade of interleukin-23 warrants further 
evaluation as treatment for Crohn’s disease.  
Funding: Boehringer Ingelheim. 
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Research in context  
Evidence before this study 
We searched PubMed for English language articles using the terms “Crohn’s disease’’, 
“biologic therapy”, “adalimumab”, “infliximab”, “certolizumab pegol”, “vedolizumab”, 
“ustekinumab”, and “IL-23” to identify controlled clinical trials published up to 28 March 
2018, with no start date restrictions. In the US and Europe, current biologic therapies 
approved for the treatment of moderate-to-severe Crohn’s disease include tumour necrosis 
factor (TNF) antagonists adalimumab, infliximab, and certolizumab pegol, the integrin 
antagonists, vedolizumab and natalizumab (US only), and the interleukin-12 and interleukin-
23 inhibitor, ustekinumab. Treatment regimens are aimed at inducing remission followed by 
maintenance therapy. Despite more therapeutic options, there are a number of patients in who 
these therapies have limited efficacy (primary nonresponse) or who lose response over time 
(secondary nonresponse) or evoke adverse effects; thus, new therapies targeting different 
inflammatory pathways are needed.  
Previously, we reported phase 2 clinical trial results of induction treatment with two 
intravenous (IV) dose levels (200 mg and 600 mg every 4 weeks) of risankizumab, a 
monoclonal antibody targeting the interleukin-23 p19 subunit, in treatment-experienced 
patients with moderate-to-severe Crohn’s disease. Risankizumab was superior to placebo in 
achieving clinical response or remission at week 12, demonstrating proof-of-concept. 
 
Added value of this study 
This study reports the findings for two further treatment periods from the previously reported 
phase 2 clinical trial (Period 1): a second open-label IV induction treatment with 600 mg 
risankizumab every 4 weeks (Period 2) for those patients not in deep remission after the first 
12 weeks induction treatment; and an open-label maintenance treatment period with 
subcutaneous (SC) 180 mg risankizumab every 8 weeks (Period 3) for patients in clinical 
remission at the end of Period 2. For patients not in deep remission at week 12, the results at 
week 26 demonstrate that further open-label induction treatment with IV 600 mg 
risankizumab every 4 weeks was effective in achieving greater clinical remission rates than 
those observed at week 12. Period 3 results suggest that open-label SC 180 mg risankizumab 
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every 8 weeks was an effective therapy to maintain clinical remission up to week 52 in 
patients who were in clinical remission at week 26.  
 
Implications of all the available evidence 
Evidence from studies with other biological agents suggests that some patients, particularly 
those previously exposed to TNF antagonists, may take longer to achieve remission than TNF 
antagonist-naïve patients. Ninety-three percent of patients enrolled in this study had been 
previously treated with at least one TNF antagonist and 79% had failed at least one such 
treatment due to inadequate response, loss of response, or intolerance. Extended open-label 
induction treatment with IV 600 mg risankizumab in patients who were not in deep remission 
at week 12 was effective in increasing clinical response and remission rates at week 26. The 
results also suggest that open-label SC 180 mg risankizumab was effective for maintenance 
of clinical remission at week 52, although a maintenance placebo arm was not included in 
this phase II study. Based upon these results, specific blockade of interleukin-23 with 
risankizumab appears to be a promising new approach for the induction of response and 
maintenance treatment of Crohn’s disease, and is currently undergoing phase III evaluation.  
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Introduction 
Crohn’s disease is a life-long, relapsing, remitting inflammatory disease of the 
gastrointestinal tract with symptoms of abdominal pain, weight loss, and chronic diarrhoea.1,2 
The medical management of Crohn’s disease is based upon the use of corticosteroids, and 
immunosuppressive agents such as thiopurines or methotrexate, with the aim of controlling 
mucosal inflammation and inducing clinical remission.1,3 Whilst corticosteroids are 
successful for induction of remission, they are ineffective as maintenance therapy and are 
associated with an increased risk of adverse events such as serious infection.1 The advent of 
biological agents that selectively target cytokines or integrins provides an alternative 
treatment option for patients with moderate-or-severe Crohn’s disease; however, these 
therapies are not universally effective, lose effectiveness over time, and may also predispose 
patients to infections.1,4-6  
Interleukin-23 plays a key role in the induction and function of T helper 17-type cells, innate 
lymphoid cells, γδ T cells, and natural killer cells responsible for tissue inflammation, 
destruction, and aberrant tissue repair involved in the pathology of several immune-related 
disorders, including Crohn’s disease.7-12 Furthermore, polymorphisms in the interleukin-23 
receptor gene are associated with susceptibility to both Crohn’s disease and ulcerative 
colitis.7 Blockade of the interleukin-23 pathway by biologics that target interleukin-17 or its 
receptor (brodalumab, ixekizumab, secukinumab), interleukin-23 (guselkumab, 
risankizumab, tildrakizumab), or interleukin-12 and interleukin-23 (ustekinumab) have 
shown efficacy for the treatment of psoriasis, and both risankizumab and ustekinumab have 
also shown efficacy in Crohn’s disease.13-16 Conversely, biological agents that specifically 
target interleukin-17 or the interleukin-17 receptor exacerbate Crohn’s disease, indicating 
differences between the role of interleukin-12/interleukin-23 and interleukin-17 in psoriasis 
compared with Crohn’s disease.17-19 
Risankizumab (BI 655066/ABBV-066) is a humanised monoclonal IgG1 antibody targeting 
the interleukin-23 p19 subunit,20 currently under evaluation in Crohn’s disease, psoriasis, 
psoriatic arthritis, and asthma. In a randomised, double-blind, phase 2 study in patients with 
moderately to severely active Crohn’s disease, most of whom had previously received at least 
two TNFα antagonists, intravenous induction therapy with risankizumab (200 mg or 600 mg 
at weeks 0, 4, and 8) was superior to placebo in achieving clinical remission and endoscopic 
remission at week 12.21 The greatest treatment response was achieved with 600 mg 
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risankizumab, which resulted in clinical remission for 37% of patients compared with 15% of 
patients receiving placebo (difference 20·9%; p=0·025). Since evidence from studies with 
other biological agents suggests that some patients, particularly those with extensive previous 
treatment with TNF antagonists, may take longer to achieve remission,1,22 this study included 
a 12-week second phase (Period 2) of open-label induction treatment with intravenous 600 
mg risankizumab every 4 weeks for patients who did not achieve deep remission, defined as 
both clinical remission (Crohn’s Disease Activity Index [CDAI] of <150) and endoscopic 
remission (Crohn’s Disease Endoscopic Index of Severity [CDEIS] ≤4 [≤2 for patients with 
isolated ileitis]) at week 12; followed by 26 weeks of open-label maintenance therapy (Period 
3) with subcutaneous 180 mg risankizumab every 8 weeks for patients in clinical remission. 
Herein, we report the safety and additional efficacy endpoints from these open-label 
treatment periods. 
 
Methods 
Study design 
This randomised, double-blind, placebo-controlled phase 2 study enrolled patients with 
moderate-to-severe active Crohn’s disease at multiple sites in North America, Europe, and 
Southeast Asia.21 There were three treatment periods: Period 1 (weeks 0–12), double-blind 
intravenous therapy; Period 2 (weeks 14–26), open-label intravenous therapy (or washout for 
patients in deep remission at week 12); and Period 3 (weeks 26–52), subcutaneous therapy 
(see appendix, p 3). The primary efficacy endpoint (i.e. the proportion of patients in clinical 
remission, defined by a CDAI of <150 at the end of Period 1 (week 12), has been previously 
reported;21 here, we report additional and exploratory endpoints for Periods 2 and 3. 
The study protocol was approved by the institutional review board or ethics committee at 
each participating centre. Safety data were periodically evaluated by an independent data 
monitoring committee. Written, informed consent was provided by all patients. 
Patients  
A complete description of the inclusion and exclusion criteria has been reported previously.21 
In brief, eligible patients were adults (aged 18–75 years) who had been diagnosed with 
Crohn’s disease for at least 3 months and who had moderate-to-severe symptoms at 
screening, defined by a CDAI23 of 220–450, with mucosal ulcers in the ileum or colon (or 
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both), and a CDEIS23 of at least 7 (or ≥4 for patients with isolated ileitis) on ileocolonoscopy 
scored by a blinded central reader.  
Randomisation and masking 
During the previously reported Period 1 of the study, patients were randomised (1:1:1, with 
stratification by previous exposure to TNF antagonists) to receive 200 mg risankizumab, 600 
mg risankizumab, or placebo.21 Periods 2 and 3 were open label and were not randomised. 
Procedures 
In Period 1, patients received either risankizumab 200 mg, risankizumab 600 mg, or placebo 
by intravenous infusion at weeks 0, 4, and 8. In Period 2, patients who were not in deep 
remission (defined as clinical and endoscopic remission) at the end of Period 1 (week 12) 
received open-label risankizumab 600 mg intravenous infusion at weeks 14, 18, and 22. 
Patients who were in deep remission at week 12 entered a washout phase until week 26. If 
these patients experienced a disease flare during this period (including the week 26 visit), 
defined as an increase in CDAI of ≥70 points compared to week 12, and a CDAI of ≥220, 
patients underwent an ileocolonoscopy. If the CDEIS was ≤4 (or ≤2 for patients with initial 
isolated ileitis), patients were to continue washout until week 26; otherwise they were to 
restart Period 2 and receive open-label risankizumab 600 mg intravenous infusions every 4 
weeks for 12 weeks. At the end of Period 2 (week 26), patients who were not in clinical 
remission stopped the study. Patients who were in clinical remission at week 26 could enter 
Period 3, and receive maintenance therapy with subcutaneous risankizumab 180 mg at weeks 
26, 34, 42, and 50. The maintenance dosing regime was selected based on the 
pharmacokinetics and available formulation of risankizumab, and the clinical results 
observed in patients with plaque psoriasis that suggested an extended clinical effect and the 
expectation of higher clearance in patients with CD.24 
Outcomes  
Efficacy outcomes during Period 2 included the proportions of patients in clinical remission 
(CDAI of <150) or clinical response (CDAI of <150 or a reduction from baseline of at least 
100 points). Period 3 outcomes included clinical remission or response, endoscopic remission 
(CDEIS ≤4 or ≤2 for patients with baseline-isolated ileitis), endoscopic response (>50% 
CDEIS reduction from baseline), mucosal healing (absence of mucosal ulceration), and deep 
remission (clinical remission plus endoscopic remission). In addition, serum C-reactive 
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protein (CRP), faecal calprotectin (FCP), and faecal lactoferrin (LF) concentrations were 
measured.  
During Periods 2 and 3, the CDAI was assessed at every treatment visit as well as at the end 
of each period (weeks 26 and 52). CDEIS was assessed by a blinded and independent central 
reader at the end of Period 3 (week 52). CRP, FCP, and LF were assessed at weeks 18, 26, 
34, 50, and 52. Plasma samples were collected at every study visit and were used to 
determine risankizumab concentrations and to assess the immunogenicity of risankizumab. 
Assay methodologies have been previously described.21 
Safety endpoints consisted of adverse events, serious adverse events, tolerability, changes in 
vital signs and physical examination, discontinuation of therapy because of adverse events, 
laboratory assessments at all study visits, and 12-lead electrocardiogram at weeks 26 and 52.  
 
Statistical methods 
Endpoints for Periods 2 and 3 were summarised descriptively, unless specified. The efficacy 
analysis population for Period 2 included patients who received at least one dose of 600 mg 
intravenous risankizumab during Period 2 (P2-treated) and did not include patients who were 
in washout. For Period 3, the efficacy analysis population included all patients who received 
at least one dose of study drug during the open-label subcutaneous period (full analysis set; 
FAS-P3). Post-hoc, stepwise selection logistic regression analyses were used to explore the 
predictive potential of baseline factors (CDAI, duration of disease, abdominal pain, stool 
frequency, corticosteroids use, TNF antagonist use, and the presence of draining fistulas) for 
week 52 clinical or endoscopic remission or response. These post-hoc regression analyses 
were conducted using the FAS-P3 Period 1 treatment group assignment as one factor. 
The full safety population included all randomised patients who received at least one dose of 
the study drug, and was further divided by study period. The incidence of treatment-emergent 
adverse events per 100 patient-years was estimated for exposure to 200 mg or 600 mg 
intravenous risankizumab during Period 1, 600 mg intravenous risankizumab during Period 2, 
180 mg subcutaneous risankizumab during Period 3, and for all patients exposed to 
risankizumab (all-exposure safety population; Periods 1–3). 
This trial is registered with ClinicalTrials.gov, number NCT02031276. 
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Role of the funding source 
The study funder was involved in the study design, data collection, and data analysis. All 
authors had full access to all data in the study, agreed to submit these data for publication, 
were involved in writing the manuscript, and agreed upon the final content of the paper. The 
study funder provided funding for editorial assistance in manuscript preparation. The 
corresponding author had final responsibility for the decision to submit for publication. 
 
Results 
Between March 2014 and September 2015, 213 patients were screened and 121 were 
randomised (figure 1). The baseline demographics and disease characteristics of patients, 
which have been reported previously,21 were similar across treatment groups; key parameters 
are reported in table 1. The mean (standard deviation) duration of Crohn’s disease at study 
entry was 13 (9) years. Of the 121 patients randomised for Period 1, 115 received at least one 
dose of risankizumab (all-exposure safety population). A total of 107 patients continued to 
Period 2: 13 discontinued during Period 121 and one patient declined to continue 
participation.  
Among the 107 patients from the three original randomised groups entering Period 2, 101 
(those not in deep remission) received treatment with 600 mg intravenous risankizumab (P2-
treated): 33 from the Period 1 placebo group and 34 from each of the Period 1 risankizumab 
groups (figure 1). Six patients who were in deep remission at week 12 (five from the 600 mg 
risankizumab group and one from the 200 mg risankizumab group) entered the washout 
phase, did not meet flare criteria during Period 2, and did not receive treatment with 
risankizumab during Period 2.  
The proportion of P2-treated patients with clinical response or remission increased steadily 
from week 12 to week 26 (figure 2A). In all three original randomisation groups, the 
proportion of patients with clinical remission at week 26 was greater than that observed at 
week 12, respectively (table 2): 18/33 (55%) versus 6/33 (18%) for the placebo group, 20/34 
(59%) versus 7/34 (21%) for the 200 mg risankizumab group, and 16/34 (47%) versus 9/34 
(26%) for the 600 mg risankizumab group (see appendix, p 4). Seven patients discontinued 
intravenous 600 mg risankizumab during Period 2 due to patient withdrawal (n=3), 
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worsening disease (n=1), and other reasons (lack of efficacy; n=3). Mean CDAI decreased 
from week 12 to week 26 (figure 2B) 
Period 3 (FAS-P3) included 55 P2-treated patients who were in clinical remission at week 26, 
six patients who had been in deep remission at week 12 (all of whom were in clinical 
remission at week 26), plus one more patient included in a deviation from protocol despite 
not achieving clinical remission at the end of Period 2 (figure 1). Eight patients discontinued 
subcutaneous risankizumab during Period 3 due to: protocol violation (n=2, including the 
aforementioned patient), patient withdrawal (n=3), adverse events (n=2), and other (n=1). 
The remaining 54 patients completed 52 weeks of treatment.  
During Period 3, the proportion of patients in clinical remission declined slightly by week 34, 
but was then stable to the end of the study (figure 2A). At week 52, the proportion of patients 
in clinical remission was 71% and the proportion with clinical response was 81% (table 2). 
Clinical remission and response rates were similar across the three original Period 1 
randomization groups; however, rates of endoscopic remission/response and mucosal healing 
were highest in patients who had been treated with the 600 mg dose of risankizumab in 
Period 1 (table 2). Mean CDAI was stable through Period 3 (figure 2B) 
At week 52, 18 patients in total were in deep remission. Five of the six patients who had been 
in deep remission at week 12 were also in deep remission at week 52. During Periods 2 and 3, 
four patients maintained clinical remission at all visits, another patient maintained remission 
despite a brief increase in CDAI to 154·5 during Period 2, while the other patient showed 
fluctuating CDAI and lost remission at the last visit (see appendix, p 5). All patients who 
were in deep remission at week 12 were characterised by a steep decrease in CDAI during 
Period 1 (see appendix, p 5).  
C-reactive protein, FCP, and LF concentrations were all reduced in patients receiving 
risankizumab. Reductions from baseline were similar between Periods 1 and 2 and 
maintained throughout Period 2; during Period 3, which only included patients in clinical 
remission, concentrations of C-reactive protein, FCP, and LF were further reduced and 
maintained to week 52 (figure 3).  
Logistic regression analysis of the FAS-P3 population with Period 1 treatment group 
assignment as one factor did not identify any baseline factors (CDAI, duration of disease, 
disease location [ileal/colonic], abdominal pain, stool frequency, corticosteroids use, TNF 
antagonist use, or the presence of draining fistulas) predictive of week 52 clinical remission 
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or response (data not shown). After the step 0 of the intercept entered, no additional effects 
met the 0·05 significance level for entry into the model. 
Risankizumab mean trough concentrations in patients who received intravenous 600 mg 
risankizumab during Period 2 (35·5 µg/mL) were similar to those observed in patients who 
received intravenous 600 mg risankizumab during Period 1 (34·2 µg/mL). As expected, 
consistent with the reduction in dose to 180 mg SC every 8 weeks in patients who rolled over 
to Period 3, risankizumab concentrations decreased considerably (from week 34) and 
approximately attained near steady-state levels by week 42 (~4 µg/mL). Among patients with 
pharmacokinetic data at week 50, risankizumab median trough plasma concentrations were 
not distinctly different between patients in clinical remission (3·53 µg/mL; n=37) and those 
who continued to experience active disease (3·27 µg/mL; n=9). Also at week 50, median 
trough plasma concentrations were similar between subjects who were also receiving a stable 
dose of immunomodulators (azathioprine, 6-mercaptopurine or methotrexate; median 3·7 
µg/mL, N=23) versus those who were not receiving any other immunomodulator (median 2·9 
µg/mL, N=29). Of those patients who entered the washout phase during Period 2, their 
median trough plasma concentrations (3·5 µg/mL, N=6) at week 50 were similar to those 
who had received 600 mg risankizumab during Period 2 (3·3 µg/mL, N=46). 
Treatment-emergent anti-drug antibodies (ADAs) were observed in 8% of patients who 
received at least one dose of risankizumab (nine out of 108 patients with evaluable samples at 
baseline and post-treatment initiation). The time to ADA positivity ranged between 12 and 18 
weeks post start of treatment and most were transient with low titre values. None of the 
ADA-positive patients had neutralising antibodies and no association was detected between 
the presence of ADA and risankizumab plasma concentrations. 
Safety results for the double-blind, randomised treatment period (Period 1) have been 
reported previously.21 The frequencies of treatment-emergent adverse events per 100 patient-
years of exposure to risankizumab for the individual periods are shown in table 3. No new 
safety signals were identified in Periods 2 and 3 compared with Period 1. Treatment-
emergent adverse events most frequently experienced during treatment with risankizumab 
were: arthralgia (22%), headache (20%), abdominal pain (18%), nasopharyngitis (16%), 
nausea (16%), and pyrexia (13%). Most treatment-emergent adverse events were mild or 
moderate in severity and were considered by the investigator to be unrelated to study 
treatment. Discontinuation of risankizumab due to a treatment-emergent adverse event 
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occurred in one patient (1%) during Period 2 (“condition aggravated”) and two patients (3%) 
during Period 3 (both for worsening of Crohn’s disease, one of which was recorded as a 
serious adverse event). Serious adverse events were experienced by 11 patients (11%) in 
Period 2 and seven patients (11%) in Period 3; those occurring in two or more patients in 
either period were worsening of Crohn’s disease (three patients), intestinal obstruction (four 
patients), all in Period 2.  
Serious infections were reported in five patients (4%) during treatment with risankizumab; 
each serious infection (anal abscess, appendicitis, incision site abscess, osteomyelitis, and 
pneumonia) was observed in individual patients (see appendix, p 5). Hepatic disorder or 
drug-induced liver injury adverse events were reported in seven patients (6%) treated with 
risankizumab; all adverse events were grade 1 or 2, and none met the criteria for Hy’s Law. 
No systemic/anaphylactic reactions, neoplasia or clinically meaningful changes in vital signs 
were observed in patients treated with risankizumab in any study period, and there were no 
consistent trends observed in clinical laboratory evaluations.  
 
Discussion 
As previously reported, the week 12 Period 1 induction results of this phase 2 study showed 
that blockade of interleukin-23 p19 with risankizumab was superior to placebo in achieving 
clinical remission and clinical response in patients with moderate-to-severe, treatment-
refractory, Crohn’s disease.21 All efficacy outcomes at week 12 favoured the 600 mg 
risankizumab dose, suggesting that the higher dose is superior to the lower dose as induction 
therapy.21  
For patients not in deep remission at week 12, the results at week 26 indicate that treatment 
with open-label intravenous 600 mg risankizumab was effective in achieving greater clinical 
remission rates than those observed at week 12. Switching from placebo to 600 mg 
risankizumab resulted in the clinical remission rate rising from 18% to 55%, confirming the 
efficacy results from the initial blinded induction period. Dose escalation from 200 mg in 
Period 1 to 600 mg risankizumab in Period 2 more than doubled the percentage of patients in 
clinical remission (from 21% at week 12 to 59% at week 26, not including the one patient 
who had been in deep remission at week 12), which is supportive of the dose-dependent 
efficacy noted in Period 1 (albeit Period 2 treatment was open-label). Even among patients 
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originally randomised to 600 mg risankizumab, extended treatment duration at the same dose 
was associated with a numerical increase in clinical remission rates (from 26% to 47%, not 
including the five patients who had been in deep remission at week 12), suggesting that some 
patients might benefit from extended 600 mg induction treatment or from a shorter induction 
duration with a higher dose than 600 mg intravenous risankizumab. Bearing in mind that 
most patients in this study had failed one or more TNF antagonists, this finding is consistent 
with other biological agents that suggest patients with extensive previous treatment with TNF 
antagonists may take longer to achieve remission.1,22 All patients in deep remission at week 
12 who entered the washout phase and received no treatment in Period 2 were still in clinical 
remission at week 26. Larger phase 3 trials are ongoing, which will allow the evaluation of 
predictors of clinical remission. 
Period 3 results suggest that open-label subcutaneous risankizumab 180 mg was an effective 
therapy to maintain clinical remission up to week 52 in patients who were in clinical 
remission at week 26, including those who had achieved deep remission at week 12 and were 
in washout during Period 2. The rate of deep remission was greater at the end of Period 3 
than it was at week 12, supporting the hypothesis that endoscopic remission commonly 
follows clinical remission with increasing duration of treatment. The lack of correlation 
between risankizumab plasma levels and remission status in Period 3 could be attributed to 
the between-subject variability in sensitivity for the drug effect and the fact that a single 
maintenance dose level was evaluated in the study. Therefore, at the steady-state exposures 
with 180 mg SC maintenance dose, some patients may not sustain the response because of 
lower sensitivity to the drug compared with patients that sustain the response, while both 
categories have comparable plasma exposures. It remains to be seen whether higher 
maintenance doses can maintain remission in a larger proportion of patients. The highest rates 
of CDEIS remission, CDEIS response, and mucosal healing at week 52 were observed in 
patients who were assigned to risankizumab 600 mg during Period 1, suggesting that higher 
initial drug exposure increases the endoscopic resolution of disease activity.  
Overall, risankizumab was well tolerated with no new safety signals detected during extended 
intravenous dosing nor during the subcutaneous treatment period. Serious adverse events 
reported in two or more patients treated with risankizumab were primarily gastrointestinal in 
nature and may reflect underlying disease. 
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The study had some limitations. First, a relatively small number of patients was evaluated, 
preventing robust sub-group analysis of clinically relevant populations. In particular, the 
limited number of TNFα antagonist-naïve patients studied precludes any comment on the 
relative efficacy of risankizumab to those with prior TNFα antagonist exposure. Second, the 
endoscopic outcomes used in the study have not been fully validated. However, this is a 
general limitation of studies in this field and the definitions used are consistent with expert 
panel recommendations.25,26 Third, during Periods 2 and 3, patients received open-label 
dosing which may have increased the perceived efficacy of risankizumab therapy for 
subjective endpoints such as the CDAI. Specifically, the lack of a control arm during these 
periods prevents us from drawing strong conclusions regarding the efficacy of risankizumab 
as a maintenance agent. Finally, a plateauing of the dose–response was not demonstrated 
during Period 1, suggesting that a dose higher than 600 mg may result in increased efficacy. 
Furthermore, no subcutaneous dose ranging was performed during Period 3, therefore the 
optimal dose for the maintenance of clinical remission was not identified.  
In conclusion, these results suggest that extended treatment with intravenous risankizumab 
600 mg in patients with moderate-to-severe, treatment-refractory Crohn’s disease, who were 
not in deep remission at week 12, is effective in increasing clinical response and remission 
rates at week 26. The results also suggest that open-label subcutaneous risankizumab 180 mg 
is effective in the maintenance of clinical remission at week 52.  
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Table 1: Summary baseline demographics and disease characteristics of patients who 
entered study Period 2 (grouped by originally randomised induction treatment) 
 
Placebo 
(n=33) 
Risankizumab  
 
All  
(N=107)  
200 mg 
(n=35) 
600 mg 
(n=39) 
Age (years), mean ± SD 36 ± 14 39 ± 13 40 ± 13 39 ± 13 
Male sex, n (%) 14 (42) 15 (43) 16 (41) 45 (42) 
Duration of disease 
(years), mean ± SD 
 
12 ± 10 
 
15 ± 9 
 
14 ± 10 
 
14 ± 10 
CDAI, median (IQR) 287 (246–365) 311 (258–374) 298 (246–330) 297 (246–358) 
CDEIS, median (IQR) 11 (8–18) 12 (9–16) 12 (8–16) 12 (9–17) 
CRP (mg/L), median 
(IQR) 
10 (3–24) 10 (4–29) 8 (2–29) 10 (3–29) 
Disease site, n (%) 
Ileum only 
Ileum and colon 
Colon only 
 
3 (9) 
19 (58) 
11 (33) 
 
4 (11) 
24 (69) 
7 (20) 
 
6 (15) 
19 (49) 
14 (36) 
 
13 (12) 
62 (58) 
32 (30) 
Prior TNF antagonist 
use, n (%) 
1  
2 
≥3 
 
 
9 (27) 
16 (48) 
6 (18) 
 
 
8 (23) 
18 (51) 
7 (20) 
 
 
9 (23) 
22 (56) 
5 (13) 
 
 
26 (24) 
56 (52) 
18 (17) 
CDAI, Crohn’s Disease Activity Index; CDEIS, Crohn’s Disease Endoscopic Index of 
Severity; CRP, C-reactive protein; IQR, interquartile range; SD, standard deviation; TNF, 
tumour necrosis factor. 
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Table 2: Clinical (weeks 26 and 52) and endoscopic (week 52) endpoints for patients 
receiving treatment with open-label 600 mg IV risankizumab and open-label 180 mg SC 
risankizumab by original Period 1 treatment group and total  
Week 26: Period 2 post open-label 600 mg IV risankizumab treatment*  
Original treatment 
allocation in Period 
1, n (%) 
Placebo 
(n=33) 
Risankizumab 
Total 
(N=101) 
200 mg 
(n=34) 
600 mg 
(n=34) 
Clinical remission 18 (55) 20 (59) 16 (47) 54 (53) 
Clinical response 24 (73) 26 (76) 24 (71) 74 (73) 
Week 52: Period 3 post open-label 180 mg SC risankizumab treatment 
Original treatment 
allocation in Period 
1, n (%) 
Placebo 
(n=19†) 
Risankizumab 
Total 
(N=62) 
200 mg 
(n=22‡) 
600 mg 
(n=21§) 
Clinical remission 15 (79) 13 (59) 16 (76) 44 (71) 
Clinical response 16 (84) 17 (77) 17 (81) 50 (81) 
Endoscopic 
remission 
6 (32) 5 (23) 11 (52) 22 (35) 
Endoscopic 
response 
10 (53) 9 (41) 15 (71) 34 (55) 
Deep remission 6 (32) 3 (14) 9 (43) 18 (29) 
Mucosal healing 4 (21) 4 (18) 7 (33) 15 (24) 
*Endoscopies were not conducted at week 26, thus only clinical endpoints are reported at this 
time point. †A protocol deviation resulted in one patient who was not in clinical remission at 
week 12 receiving a single SC treatment at the beginning of Period 3. ‡Includes one patient 
who had been in washout during Period 2 after achieving deep remission at week 12, and one 
patient who had two CDAI measures at week 26: the value used for the efficacy calculation 
(CDAI of 166) differed from the value used to determine eligibility for entry into Period 3 
(CDAI of 110). §Includes five patients who had been in washout during Period 2 after 
achieving deep remission at week 12. 
Clinical endpoints at week 26 for patients (those not in deep remission at week 12) entering 
Period 2 treatment with 600 mg open-label IV risankizumab, and clinical and endoscopic 
endpoints at week 52 for patients in clinical remission entering Period 3 treatment with 180 
mg open-label SC risankizumab are reported by original treatment randomisation. P2-treated 
and FAS-P3 were used for these analyses, using NRI for missing values. Clinical response is 
defined as a CDAI of <150 points or a CDAI reduction from baseline of ≥100 points. Clinical 
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remission is defined as a CDAI of <150. Endoscopic response is defined as a >50% reduction 
in CDEIS from baseline to week 52. Endoscopic remission is a CDEIS of ≤4 at week 52 (for 
patients with baseline-isolated ileitis, CDEIS of ≤2). Deep remission is defined as clinical 
remission and endoscopic remission at week 52.  
CDAI=Crohn’s Disease Activity Index; CDEIS=Crohn’s Disease Endoscopic Index of 
Severity; FAS=full analysis set; FAS-P3=FAS Period 3; IV=intravenous; NRI=non-response 
imputation; SC=subcutaneous. 
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Table 3: Overview of treatment-emergent adverse events with risankizumab treatment 
per 100 PYs by treatment period, and all-exposure risankizumab safety population 
(Periods 1–3) 
Events (events/100 PY) 
Period 2 
600 mg IV 
(P2-treated) 
N=101, 
PYs=28·8 
Period 3 
180 mg SC 
(FAS-P3) 
N=62, 
PYs=43·3 
All-exposure 
risankizuma
b safety 
population* 
N=115, 
PYs=109·1 
Any adverse event 
Severe 
Possibly drug related† 
Leading to discontinuation of drug 
Leading to death 
267 (927·1) 
19 (66·0) 
28 (97·2) 
1 (3·5) 
0 
165 (381·1) 
6 (13·9) 
23 (53·1) 
2 (4·6) 
0 
719 (659·0) 
36 (33·0) 
81 (74·2) 
10 (9·2) 
0 
Serious adverse event 18 (62·5) 9 (20·8) 46 (42·2) 
Infections  
Serious  
Opportunistic 
Tuberculosis 
Fungal 
37 (128·5) 
1 (3·5) 
0 
0 
3 (10·4) 
32 (73·9) 
1 (2·3) 
0 
0 
0 
107 (98·1) 
5 (4·6) 
3 (2·7) 
1 (0·9) 
8 (7·3) 
Malignancies 0 0 0 
Infusion-related reaction 3 (10·4) NA 4 (3·7) 
Drug-induced liver injury or hepatic 
disorder‡ 
5 (17·4) 6 (13·9) 13 (11·9) 
Cardiac arrhythmias 1 (3·5) 0 1 (0·9) 
Systemic hypersensitivity/anaphylactic 
reactions 
20 (69·4) 12 (27·7) 49 (44·9) 
Depression, suicidal ideation, and 
behaviour 
1 (3·5) 2 (4·6) 5 (4·6) 
Treatment-emergent adverse events are defined as events that begin or worsen either on or 
after the first dose of the study drug, and within 105 days after the last dose of the study drug.  
*Includes all patients who received at least one dose of risankizumab during Periods 1–3. 
†Assessed by study investigator. ‡All adverse events were grade 1 or 2, and none met the 
criteria for Hy’s Law. 
FAS=full analysis set; IV=intravenous; PY=patient-years; SC=subcutaneous.  
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Figure 1: Patient disposition 
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*One patient received open-label SC risankizumab in Period 3 despite not achieving clinical remission at the end of Period 2 (protocol violation); the patient discontinued 
risankizumab and is counted among the eight patients discontinuing treatment during Period 3. One additional subject had two CDAI values within the visit window for week 
26; the value used for the efficacy calculation (CDAI of 166) differed from the value used to determine eligibility for entry into Period 3 (CDAI of 110). 
AE=adverse event; IV=intravenous; SC=subcutaneous 
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Figure 2: Time course of clinical response, remission, and CDAI over time through Periods 2 (n=101)* 
and 3 (n=62) 
 
 
*For Period 2, data shown do not include patients who were in deep remission at week 12 and who entered the 
washout period (N=6). FAS was used for this analysis, using LOCF for missing values and stratified Cochran–
Mantel–Haenszel tests. For clinical response and remission percentage of patients ±95% CI are shown; for 
CDAI, mean ± SD are shown. 
CDAI=Crohn’s Disease Activity Index; CI=confidence interval; FAS=full analysis set; IV=intravenous; 
LOCF=last observation carried forward; SC=subcutaneous; SD=standard deviation. 
  
27 
 
 
Figure 3: Median change in CRP, FCP, and LF over time through Periods 2 (n=101)* and 3 (n=62) 
 
†For Period 2, data shown do not include patients who were in deep remission at week 12 and who entered the 
washout period (N=6). FAS was used for this analysis, using LOCF for missing values and stratified Cochran–
Mantel–Haenszel tests. Median change from Period 1 baseline values and interquartile range are reported. 
FAS=full analysis set; hs-CRP=high sensitivity C-reactive protein; IV=intravenous; LOCF= last observation 
carried forward; SC=subcutaneous.  
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Principal investigators and participating study sites  
Investigator Study Site Patients recruited 
Prof. Dr Edouard Louis University Hospital CHU of Liège, Liège, Belgium 9 
Prof. Dr Julián Panés Hospital Clínic de Barcelona, IDIBAPS, CIBERehd, Barcelona, 
Spain 
9 
Prof. Dr Marc Ferrante UZ Leuven, Leuven, Belgium 9 
Prof. Dr Denis Franchimont Hôpital Universitaire Erasme, Brussels, Belgium 7 
Prof. Dr Arthur Kaser University of Cambridge, Addenbrooke’s Hospital, Cambridge, 
UK 
6 
Prof. Dr Geert D’Haens Academic Medical Center, Amsterdam, Netherlands 6 
Prof. Olivier Dewit Cliniques Universitaires Saint-Luc, Brussels, Belgium 6 
Prof. Dr Ursula Seidler Medizinische Hochschule Hannover, Hannover, Germany 6 
Prof. Dr Byung Ik Jang Yeungnam University Medical Center, Daegu, South Korea 4 
Dr Ronald Fogel Clinical Research Institute of Michigan, Chesterfield, MI, USA 4 
Dr Philip Ginsburg Medical Research Center of Connecticut, Hamden, CT, USA 4 
Dr Robert Petryka ViVamed, Warsaw, Poland 4 
Dr Filip Baert AZ Delta, Roeselare, Belgium 3 
Dr Peter Bossuyt Imelda vzw, Bonheiden, Belgium 3 
Dr Young-Ho Kim Samsung Medical Center, Seoul, South Korea 3 
Dr Satish Keshav Oxford University Hospitals NHS Foundation Trust, Oxford, UK 3 
Prof. Dr Kyung-Jo Kim Asan Medical Center, Seoul, South Korea 3 
Dr John Mansfield Newcastle upon Tyne Hospitals NHS Foundation Trust, 
Newcastle, UK 
3 
Prof. Dr Dong Il Park Kangbuk Samsung Hospital, Seoul, South Korea 3 
Dr Christian Selinger Leeds Teaching Hospitals NHS Trust, Leeds, UK 3 
Prof. Dr Gerd Bouma VU University Medical Center, Amsterdam, Netherlands 2 
Dr Jae Hee Cheon Severance Hospital, Seoul, South Korea 2 
Dr Javier Pérez Gisbert Hospital Universitario de La Princesa, Madrid, Spain 2 
Dr Jordi Guardiola Hospital Universitario de Bellvitge, Barcelona, Spain 2 
Prof. Dr med. Markus F. Neurath Universitätsklinikum Erlangen, Erlangen, Germany 2 
Prof. Dr Marieke Pierik Maastricht Universitair Medisch Centrum, Maastricht, the 
Netherlands 
2 
Dr William J. Sandborn UC San Diego Medical Center, San Diego, CA, USA 2 
Dr Brian G. Feagan London Health Sciences Centre, London, ON, Canada 1 
Dr Robert Hardi MGG Group Co./Chevy Chase Clinical Research, 
Chevy Chase, MD, USA 
1 
Dr Peter Hasselblatt Universitätsklinikum Freiburg, Freiburg, Germany 1 
Dr Ammar Hemaidan Advanced Medical Research Center, Port Orange, FL, USA 1 
Dr Robert Herring Quality Medical Research, Nashville, TN, USA 1 
Dr Peter Irving Guy’s and St Thomas’ Hospitals NHS Foundation Trust,  
London, UK 
1 
Dr John K Marshall McMaster University Medical Centre, Hamilton, ON, Canada 1 
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Dr Wouter Van Moerkercke AZ Groeninge, Kortrijk, Belgium 1 
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Figure S1: Study design 
 
*If CDEIS >4 (CDEIS >2 for patients with baseline-isolated ileitis), patients to receive open-label IV therapy 
(600 mg risankizumab × 3 q4w, dotted arrows). 
IV=intravenous; q4w=every 4 weeks; q8w=every 8 weeks; SC=subcutaneous 
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Figure S2: Clinical remission at week 26 by induction treatment outcome at week 12* 
 
 
*Only patients receiving treatment during Period 2 (P2-treated: n=101) were used for this analysis; the six 
patients with deep remission at week 12 were not included. The analysis used non-response imputation for 
missing values.  
CR-100 is defined as a decrease in CDAI of ≥100 points compared with baseline in patients not in clinical 
remission. 
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Figure S3: CDAI over time (to week 52) in patients with deep remission at week 1 
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Table S1: Description of serious infections 
Serious infection Description 
Anal abscess Age: 31 years, Sex: Male, Race: Asian, Weight: 61.2 kg 
Treatment in Period 1: risankizumab 600 mg IV 
Onset: Day 62, Lasting: 3 days 
Toxicity grade: Grade 1 
Relationship to study drug: No reasonable possibility  
Actions taken with study treatment: Dose not changed  
Outcome: Recovered/Resolved  
Concomitant or additional treatment given: Yes     
Appendicitis Age: 26 years, Sex: Male, Race: White, Weight: 76.2 kg 
Treatment in Period 1: Placebo  
Onset: Day 235; Lasting: 2 days 
Toxicity grade: Grade 2 
Relationship to study drug: No reasonable possibility  
Actions taken with study treatment: Dose not changed  
Outcome: Recovered/Resolved  
Concomitant or additional treatment given: Yes     
abscess surgical site 
infection 
Age: 34 years, Sex: Female, Race: White, Weight: 80.0 kg 
Treatment in Period 1: risankizumab 200 mg IV  
Onset: Day 157; Lasting: 18 days 
Toxicity grade: Grade 2 
Relationship to study drug: Reasonable possibility  
Actions taken with study treatment: Dose not changed  
Outcome: Recovered/Resolved  
Concomitant or additional treatment given: Yes     
Osteomyelitis Age: 64 years, Sex: Female, Race: White, Weight: 59.1 kg 
Treatment in Period 1: risankizumab 600 mg IV  
Onset: Day 45; Lasingt: 36 days 
Toxicity grade: Grade 3 
Relationship to study drug: Reasonable possibility  
Actions taken with study treatment: Dose not changed  
Outcome: Recovered/Resolved  
Concomitant or additional treatment given: Yes     
Pneumonia Age: 23 years, Sex: Male, Race: Asian, Weight: 63.3 kg 
Treatment in Period 1: risankizumab 200 mg IV  
Onset: Day 51; Lasting: 8 days 
Toxicity grade: Grade 3 
Relationship to study drug: No reasonable possibility  
Actions taken with study treatment: Dose not changed  
Outcome: Recovered/Resolved  
Concomitant or additional treatment given: Yes     
 
